Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

Yamaoka K, Tanaka Y.

Expert Opin Pharmacother. 2014 Jan;15(1):103-13. doi: 10.1517/14656566.2014.854771. Epub 2013 Nov 5. Review.

PMID:
24188100
2.

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.

Bannwarth B, Kostine M, Poursac N.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):753-61. doi: 10.1517/17425255.2013.789500. Epub 2013 Apr 9. Review.

PMID:
23570265
3.

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.

Vyas D, O'Dell KM, Bandy JL, Boyce EG.

Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790. Review.

PMID:
24285764
4.

Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis.

Sonomoto K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(6):443-7. doi: 10.2177/jsci.38.443. Review.

5.

[JAK inhibitor].

Yamaoka K, Tanaka Y.

Nihon Rinsho. 2013 Jul;71(7):1243-7. Review. Japanese.

PMID:
23961674
6.

Tofacitinib for treatment of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Adv Ther. 2013 Aug;30(8):713-26. doi: 10.1007/s12325-013-0047-y. Epub 2013 Aug 14. Review.

PMID:
23943546
7.

[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].

Varisco PA, So A.

Rev Med Suisse. 2014 Jan 22;10(414):187-91. French.

PMID:
24624736
8.

[Anti-rheumatic effect of JAK-inhibitors].

Yamaoka K, Maeshima K, Kubo S, Sonomoto K, Tanaka Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(2):112-7. Japanese.

9.

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Scott LJ.

Drugs. 2013 Jun;73(8):857-74. doi: 10.1007/s40265-013-0065-8. Review. Erratum in: Drugs. 2013 Sep;73(14):1647.

PMID:
23716132
10.

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.

Nakayamada S, Kubo S, Iwata S, Tanaka Y.

BioDrugs. 2016 Oct;30(5):407-419. Review. Erratum in: BioDrugs. 2016 Oct;30(5):483.

PMID:
27577235
11.

Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.

Kaur K, Kalra S, Kaushal S.

Clin Ther. 2014 Jul 1;36(7):1074-86. doi: 10.1016/j.clinthera.2014.06.018. Review.

PMID:
25047498
12.

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.

Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R.

Ann Rheum Dis. 2016 May;75(5):831-41. doi: 10.1136/annrheumdis-2014-205847. Epub 2015 Apr 22.

13.
14.

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J.

Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.

PMID:
24026258
15.

Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.

Iwata S, Tanaka Y.

Expert Rev Clin Immunol. 2016 Oct;12(10):1047-57. doi: 10.1080/1744666X.2016.1189826. Epub 2016 Jun 6. Review.

PMID:
27253519
16.

[Tofacitinib for the treatment of rheumatoid arthritis].

Tanaka Y.

Nihon Rinsho. 2016 Jun;74(6):974-80. Review. Japanese.

PMID:
27311188
17.

Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.

Cohen SB, Koenig A, Wang L, Kwok K, Mebus CA, Riese R, Fleischmann R.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):32-6. Epub 2015 Nov 17.

PMID:
26575982
18.

Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.

Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):592-598. doi: 10.1002/acr.23004.

19.

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.

MacFarlane LA, Todd DJ.

Int J Rheum Dis. 2014 May;17(4):359-68. doi: 10.1111/1756-185X.12293. Epub 2014 Jan 27. Review.

PMID:
24460872
20.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142

Supplemental Content

Support Center